Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein dachsous homolog 1 (DCHS1) is a member of the cadherin superfamily and acts as an atypical cadherin mediating calcium-dependent cell-cell adhesion in multiple tissues[1][2][3][4][6]. Expressed predominantly in fibroblasts, DCHS1 plays critical roles in the regulation of cell polarity, proliferation, and differentiation during development, and is essential for tissue morphogenesis including the heart, kidneys, lungs, brain, and skeleton[2][3][7]. DCHS1 interacts with the receptor FAT4 via heterophilic binding along its extracellular cadherin domains, forming a complex that coordinates planar cell polarity and structural organization in developing tissues[4][2]. Mutations in DCHS1 are clinically significant, causing mitral valve prolapse and syndromic developmental disorders such as Van Maldergem syndrome[3][5]. Its principal molecular function is in mediating cell adhesion and organizing cellular behavior; it is not known to be targeted by approved drugs nor to serve as a drug receptor, but its mutation status can serve as a biomarker for specific syndromic and cardiovascular conditions[3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein dachsous homolog 1 (DCHS1).